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ABSTRACT
Alzheimer’s disease (AD) is characterized neuropathologically
by an abundance of 1) neuritic plaques, which are primarily
composed of a fibrillar 42-amino-acid amyloid-b peptide (Ab), as
well as 2) neurofibrillary tangles composed of aggregates of
hyperphosporylated tau. Elevations in the concentrations of
the Ab42 peptide in the brain, as a result of either increased
production or decreased clearance, are postulated to initiate and
drive the AD pathologic process. We initially introduced a novel
class of bridged aromatics referred tg-secretase modulatoro
as g-secretase modulators that inhibited the production of
the Ab42 peptide and to a lesser degree the Ab40 peptide
while concomitantly increasing the production of the carboxyl-
truncated Ab38 and Ab37 peptides. These modulators potently
lower Ab42 levels without inhibiting the g-secretase–mediated
proteolysis of Notch or causing accumulation of carboxyl-
terminal fragments of APP. In this study, we report a large
number of pharmacological studies and early assessment of
toxicology characterizing a highly potent g-secretase modulator
(GSM), (S)-N-(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-methyl-
1H-imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine (BPN-
15606). BPN-15606 displayed the ability to significantly lower
Ab42 levels in the central nervous system of rats and mice at
doses as low as 5–10 mg/kg, significantly reduce Ab neuritic
plaque load in an AD transgenic mouse model, and significantly
reduce levels of insoluble Ab42 and pThr181 tau in a three-
dimensional human neural cell culture model. Results from repeat-
dose toxicity studies in rats anddoseescalation/repeat-dose toxicity
studies in nonhuman primates have designated this GSM for 28-
day Investigational New Drug-enabling good laboratory practice
studies and positioned it as a candidate for human clinical trials.
Introduction
Alzheimer’s disease (AD) is pathologically characterized by
neuritic plaques and neurofibrillary tangles that result in a
significant loss of neurons and synapses in areas of the brain
important for cognition (Tanzi and Bertram, 2005). AD is an
emerging health crisis that imposes a severe economic burden
on those affected. In the absence of any disease-modifying
treatments, the costs of AD may bankrupt our healthcare
system in the next three decades (http://www.Alz.Org). Un-
fortunately, existing treatments are merely palliative, pro-
viding only temporary symptomatic benefit, and do not affect
the underlying progression of the disease.
A number of potential disease-modifying therapeutic ap-
proaches for AD either have previously failed or are currently
just beginning to be tested clinically, yet none to date have
been shown to impact disease progression (Qiu et al., 2009;
Sabbagh and Cummings, 2011). Most treatment strate-
gies currently being pursued have arisen from the genetic,
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biochemical, and morphologic data implicating the amyloid
precursor protein (APP) and the amyloid-b peptide (Ab)
products from proteolytic processing in the pathogenesis of AD
(Toyn et al., 2014). Consequentially, therapeutic strategies
have focused on inhibiting the enzymes (secretases) responsi-
ble for Ab production, thereby reducing the levels of all Ab
peptide species. Although b-site amyloid precursor protein
cleaving enzyme (BACE) inhibitors are currently under
clinical scrutiny (Portelius et al., 2014), g-secretase inhibitors
have not demonstrated efficacy and have shown significant
side effects (Fleisher et al., 2008; Coric et al., 2012). In
contrast, immunotherapy approaches that aim at clearing
deposited Ab peptides have recently shown potential against
AD; however, this is only after years of failures (Gilman et al.,
2005; Miles et al., 2013; Salloway et al., 2014). Biogen recently
reported results of a 52-week, 166-patient phase 1b clinical
trial with an anti-Ab human monoclonal antibody, aducanu-
mab, which showed a statistically significant dose-dependent
reduction of amyloid plaques as measured by florbetapir
positron emission tomography imaging, and statistically
significant reduction in cognitive decline as measured by Mini-
MentalStateExaminationandClinicalDementiaRating, relative
to placebo, lending significant support to therapeutic strategies
targeting plaque-associated Ab peptides for the treatment of AD
(Sevigny et al., 2016).
The neuritic plaques associated with AD are composed
predominantly of Ab42 (Iwatsubo et al., 1994), and the most
common biochemical phenotype observed for the more than
200 different familial AD–linked mutations is an increased
ratio of Ab42/Ab40 (Kumar-Singh et al., 2006; Potter et al.,
2013). Moreover, a large body of data points to Ab42 as the
most potently pathogenic of this family of peptides (Tanzi and
Bertram, 2005). Thus, selective attenuation of Ab42 relative
to the shorter Ab peptides (i.e., Ab40, Ab38, and Ab37) may
prove to be a novel and efficacious avenue for interrupting AD
progression (Kounnas et al., 2010; Wagner et al., 2012, 2014).
Because the Ab peptides are produced as the result of the
sequential proteolytic processing of APP by the aspartyl
protease known as g -secretase, small molecules capable of
modulating the enzyme have been intensely pursued.
Our therapeutic approach is based on the amyloid cascade
hypothesis (Hardy and Higgins, 1992) and utilizes a small
molecule g -secretase modulator to selectively attenuate the
production of Ab42 while increasing the production of trun-
cated Ab species. Whereas previous therapeutic approaches
utilizing small molecules targeting the amyloid cascade
hypothesis have been shown to be toxic (e.g., g-secretase
inhibitors such as semagacestat and avagacestat), g-secretase
modulation addresses the oligomeric-prone Ab42 peptide and
does not interfere with overall enzyme function, thereby
avoiding the inhibitor-related side effects. We view the
g-secretase modulation approach as superior to the use of
vaccines and passive immunization that require invasive
procedures and immune regulation. In addition, because
g-secretase modulators (GSMs) directly attenuate the level
of Ab42 and to a lesser degree Ab40, while increasing levels of
shorter Ab peptides (Ab38 and Ab37), they may prove to be
easier to test, evaluate, and monitor clinically than com-
pounds that inhibit the activities of either b-secretase or
g-secretase.
Beyond slowing progression in symptomatic AD, an im-
portant additional therapeutic goal of disease-modifying
approaches is to prevent AD in high-risk populations (Golde
et al., 2011). This objective will be viewed as increasingly
important if current immunotherapy and BACE inhibitor
trials reinforce evidence that intervening after the develop-
ment of abundant pathology severely limits efficacy. Inter-
vening in AD for prevention or at stages of earliest symptoms
requires many years of treatment, and a high priority is to
identify drugs that are more affordable than antibodies, and
that can be delivered orally, safely, and for decades before the
onset of AD in people at risk by virtue of genetic predisposi-
tion, risk factors, or biomarker related to presymptomatic
pathology.
Materials and Methods
Compounds
The novel GSM (S)-N-(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-
methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine (BPN-
15606) was synthesized at AlbanyMolecular Research Institute (Albany,
NY), using the methods reported in the University of California, San
Diego patent (Wagner et al., 2016). The g-secretase inhibitor N-[N-
(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester was
purchased from Sigma-Aldrich (St. Louis, MO).
Ab Enzyme-Linked Immunosorbent Assays
All Ab assays, including the anti-Ab immunoprecipitation/matrix-
assisted laser desorption/ionization time of flight, were carried out as
described previously (Wagner et al., 2014).
Notch Assays
Notch assays were carried out as described previously (Wagner
et al., 2014).
In Vitro Absorption, Distribution, Metabolism, Excretion, and
Toxicity (ADMET)
Kinetic Solubility. BPN-15606 (100 mM) was introduced into
aqueous phosphate-buffered saline (PBS) buffer pH 7.4 as a concen-
trated solution in dimethylsulfoxide (DMSO) for 1 hour. The concen-
tration of dissolved compound was measured via UV/Vis absorbance
against a calibration curve.
Functional hERG. An automated patch-clamp technique was
used to measure hERG conductance using HEK293 cells stably
transfected with the human ERG gene. Inhibition is expressed as
an IC50 value determined from the percent inhibition versus test
compound concentration curves using five concentrations of the test
compound.
Liver Microsomal Stability. BPN-15606 (1.0mM)was incubated
with microsomes and cofactor regeneration system from human, rat,
mouse, or dog for 30 minutes. Liquid chromatography (LC)/mass
spectrometry (MS) analysis was then used to measure the remaining
compound.
Microsomal Clearance. The test compound (1.0 mM) was in-
cubated with liver microsomes and cofactor regeneration system from
human, rat, mouse, or dog. LC/MS analysis was then used to measure
remaining compound at specified time points (0, 5, 10, 15, 30, and
45 minutes).
Multi-Drug Resistance Gene 1-Madin Darby Canine Kidney
(MDR1-MDCK) Permeability. Passive and active transport of
BPN-15606 across amonolayer ofMDR1-MDCKcells in two directions
(apical to basolateral and reverse) were evaluated. Permeability and
efflux ratio of the test compound were determined based on measure-
ment of compound concentration in the receiving compartment by
LC/MS analysis.
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CYP Inhibition. The test compound was coincubated with CYP-
selective probe substrates and human liver microsomes. Inhibition of
the CYPs was assessed by measuring formation of metabolites of
probe substrates by LC/tandem MS (MS/MS) analysis. Inhibition is
expressed as an IC50 value determined from the percent inhibition
versus test compound concentration curves using eight concentrations
of the test compound. CYP isoforms evaluated include 1A2, 2B6, 2C8,
2C9, 2C19, 2D6, and 3A4 (two probe substrates are used for 3A4).
CYP Induction. Test compound was incubated with cryopre-
served plateable human hepatocytes from three individual donors.
Upon incubation, CYP1A2, CYP2B6, and CYP3A4 enzyme activities
are measured using specific probe substrates with LC/MS/MS de-
tection to determine increase in enzyme activity compared with
the vehicle control (fold induction). As positive controls, known CYP
inducers are used. The acceptance criterion for assay performance
(adequacy for detecting induction by BPN-15606) was a .twofold
induction of CYP isoforms in the positive controls.
CEREP Profile. BPN-15606 (10 mM) was incubated with a panel
of 55 receptors (CEREP ExpresS, Redmond, WA) to determine
potential off-target binding activity.
Metabolite Identification. Test compound (1 mM)was incubated
at 37°C for 4 hours with cryopreserved mouse, rat, dog, monkey, or
human hepatocytes. Identification of metabolites’ molecular weights
and relative abundance of the specific metabolites was based on high
performance liquid chromatography (HPLC)/MS/MS peak areas,
and structural characterization of metabolites was accomplished by
LC/MS/MS/Q-Trap.
Bioanalytical Method
Mouse, rat, and nonhuman primate (NHP) plasma and brain ex-
tract calibration standards and quality control samples were pre-
pared in untreated plasma or brain, as follows: A primary stock
solution of 2 mg/ml analyte [BPN-15606 or N-(2-ethyl-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-
1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine (BPN-3783; internal
standard)] in DMSO was prepared, and then dilutions were per-
formed to make spiking solutions of analyte in DMSO at various
concentrations. One volume of spiking solution was added to 99
volumes of untreated plasma or brain extract to attain nominal
concentrations of standards with a final nonplasma matrix concen-
tration of 1.0%.
Plasma Extraction Method. To 50ml sample in a 2-mlmicrofuge
tube was added 0.9 ml acetonitrile containing 1600 ng/ml BPN-3783
(internal standard). Tubes were vortexed at maximum speed on a
plate vortexer 5minutes and centrifuged 10minutes at approximately
18,000g, and 20 ml supernatant was removed to a glass HPLC vial
containing 880 ml 85/15/0.1:water/acetonitrile/formic acid (v/v/v).
Brain Extraction Method. Rat or mouse brain samples were
stored frozen at 270°C and thawed to room temperature, and then
homogenized in PBS using a probe sonicator (15 seconds at 50%
maximal amplitude), using 4 ml PBS per 1 g brain tissue. To 50 ml
brain homogenate was added 0.3 ml acetonitrile containing 100 ng/ml
BPN-3783 (internal standard). Tubes were vortexed, centrifuged
10minutes at approximately 18,000g, and 75 ml supernatant removed
to a glass HPLC vial containing 800 ml 85/15/0.1:water/acetonitrile/
formic acid (v/v/v). The vials were briefly vortexed prior to LC/MS/MS
analysis.
The ultraperformance LC/MS/MS method used a Shimadzu
LC-20AD Pumps (Shimadzu, Columbia, MD), Leap Technologies
CTC HTS PAL Autosampler (Leap Tecnologies, Durham, NC), a
Phenomenex Luna C18(2), 50  2-mm, 5-mm column (Phenomenex,
Torrance, CA) operated at 20°C, and an AB Sciex QTrap 5500 mass
spectrometer with multiple reaction monitoring (SCIEX, Concord,
Ontario, Canada). The mobile phase consisted of (A) 0.1% formic acid
in water (v/v) and (B) 0.1% formic acid in acetonitrile (v/v) delivered at
1.0 ml/min using a gradient elution mode. The initial elution condition
was 2% B, which was maintained for 0.7 minute, increased to 95% B in
1 minute, and maintained for 1.7 minutes. It was then returned to 2%
B in 0.2 minute and maintained for 1.5 minutes. The MS/MS analysis
was performed using electrospray ionization, positive ion mode with
the source temperature at 600°C. The ion spray voltage was 3500 V,
and the collision energy was 40 eV for BPN-15606 and 45 eV for BPN-
3783 (internal standard).Mass to charge ratios of 419.2 (precursor ion)
and 297.1 (product ion) were used for multiple reaction monitoring of
BMS-15606. Mass to charge ratios of 422.1 (precursor ion) and 214.05
(product ion) were used for multiple reactionmonitoring of BPN-3783.
Integration and quantitation were by Analyst software.
The lower limit of quantitation (LLOQ) was 1.0 ng/ml. The range of
the plasma standard calibration curve (LLOQ) to upper limit of
quantitation was 10.0 to 10,000 ng/ml. The coefficient of determina-
tion (r2) was $0.999 in the sample analysis.
Animal Studies
All animal experiments were conducted following National Insti-
tutes of Health guidelines and were in compliance with the policies of
University of California, SanDiego Institutional Animal Care andUse
Committee and the SRI International Institutional Animal Care and
Use Committee (Palo Alto, CA).
PK in Mouse and Rat
Male CD-1 mice andmale Sprague–Dawley rats were administered
a single dose of BPN-15606 by i.v. or oral gavage (po) dose routes to
assess oral bioavailability. Mice and rats received BPN-15606 as a
single i.v. dose at 1 mg/kg (n5 5) or a single po dose at 5 mg/kg (n5 5).
Blood was collected from mice and rats at 5 (i.v. only), 15, and
30 minutes, and 1, 2, 4, 8, and 12 hours postdose for processing to
plasma. Formice, brainswere collected from both dose groups (i.v. and
po) at 1, 4, 8, and 12 hours postdose. For rats, brains were collected
from those same animals at the 12-hour time point only. Plasma,
cerebrospinal fluid (CSF), and brainswere collected at 1 hour postdose
from another group of rats treated with BPN-15606 at 1 mg/kg (i.v.).
All sampleswere analyzed byLC/MS/MS for BPN-15606 levels using a
bioanalytical method that had a LLOQ of 1 ng/ml in plasma and CSF
and 5 ng/g in brain tissue. Clinical observations were performed
immediately postdose. All animals appeared normal throughout the
study.
PK Nonhuman Primates
Male non-naive cynomolgus monkeys (NHP) were administered
BPN-15606 as a single nasogastric (po; 2 mg/kg) or i.v. (1 mg/kg) dose
to assess oral bioavailability. Whole-blood samples were collected at
specific time points and processed to plasma. Study in-life was
conducted at CharlesRiver Laboratories (Reno,NV). Pharmacokinetic
(PK) plasma samples were shipped to SRI International for de-
termination of drug concentrations. Samples were analyzed at SRI
International using the bioanalytical method described above and
validated for NHP plasma, and the LLOQ was 1 ng/ml.
PK Analysis
Data were subjected to noncompartmental analysis using WinNon-
lin Phoenix Model 200 (for extravascular administration) or Model
201 (for i.v. bolus administration) and the sparse sampling feature;
a uniform weighting factor was applied to each data set. Time to
maximum plasma concentration (Tmax) and maximum plasma
concentration (Cmax) values were determined directly from the data.
Area under the plasma concentration–time curve to the last time point
(AUClast) values were calculated using the log/linear trapezoidal
(i.v. dose) or linear up/log down trapezoidal (po dose). Values were
calculated using the plasma data from composite groups. The dose
administered was input to the program as mg/kg, and as a result no
additional corrections for individual body weights of the animals were
necessary. The following parameters and constants were determined
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for the i.v. and po groups: observed Cmax, Tmax, AUClast, area under
the plasma concentration–time curve extrapolated to infinity, termi-
nal phase elimination half-life, and mean residence time to the last
time point. The volume of distribution at steady state and clearance
were calculated using the i.v. group data. Bioavailability after oral
administration was calculated using the AUClast values for both the
i.v. and po groups.
Repeat-Dose Efficacy Studies in Mice and Rats
Male C57BL/6J mice (n5 10/dose level) andmale Sprague–Dawley
rats (n 5 14/dose level) were administered either vehicle (80%
polyethylene glycol 400 v/v; 20% sterile water v/v and 0.1% Tween
20 v/v) or BPN-15606 (10, 25, and 50 mg/kg) once daily po for
7 consecutive days (mice) or 5, 25, and 50 mg/kg once daily po for
9 consecutive days (rats). Clinical observations were performed
immediately following dosing on each day, and all animals appeared
normal throughout the study. Animals were sacrificed 4 hours
following the dosing on day 7 of the 7-day oral treatment course
(mice) and on day 9 of the 9-day oral treatment course (rats). Plasma
and brain extracts were prepared (mice and rats); CSF was aspirated
from the cisterna magnum with minimal to no blood contamination
(rats only); and tissues were frozen at 270°C. Ab peptides were
quantitated in brain extracts and plasma (mice) or CSF and plasma
(rats), as described previously, using Meso Scale multiplex kits and
the Meso Scale Sector Imager 6000 (Kounnas et al., 2010). Statistical
analysis was performed using GraphPad Prism software, and results
are expressed as mean 6 S.E.M. Analysis of variance was used to
detect a significant effect. Drug levels of BPN-15606weremeasured in
plasma and brain extracts using the bioanalytical methods detailed
above.
Acute Single-Dose Pharmacodynamics in Mice
Male C57BL/6J mice (n 5 5 per group) were administered a single
dose of either vehicle (80% polyethylene glycol 400 v/v; 20% sterile
water v/v and 0.1% Tween 20 v/v) or BPN-15606 (25 mg/kg) by po and
sacrificed at 0.5, 1, 2, 4, 8, 12, and 24 hours following the dosing.
Plasma and brain extracts were prepared, and Ab peptides were
quantitated as described previously (Kounnas et al., 2010). Statistical
analysis was performed as described above for the repeat dosing
studies.
Chronic Repeat-Dose Efficacy in Transgenic Mice
Thirty-five female double-transgenic mice, model presenilin amy-
loid precursor protein (Jankowsky et al., 2004), purchased from
The Jackson Laboratory (Bar Harbor, ME) [B6.C3-Tg (APPswe,
PSEN1dE9) 85Dbo/Mmjax, stock no. 0034829] and then bred
in-house, were used in the study at 90 days of age. The mice were
housed in a temperature-controlled roomat a constant 22°C in a 12:12-
hour light/dark cycle (lights off at 18:00), with food andwater available
ad libitum. Age-matched mice were housed by treatment group in
groups of two to four per cage. All experimental procedures were
reviewed and approved by Institutional Animal Care and Use
Committee at University of California, San Diego. Subjects were
randomly assigned to either the drug group (BPN-15606) or vehicle,
with individual groups ranging from 9 to 10 mice. Mice were treated
for 6 months with BPN-15606 at a dose of 10 mg/kg/d. For the drug
administration, BPN-15606 was milled into standard rodent chow,
processed by Research Diets (New Brunswick, NJ). All animals were
weighed three times weekly to assess any adverse effects on normal
weight gain during the 6-month treatment period. Food consumption
was determined byweighing themetal cage, including the chow, to the
nearest 0.1 g.
Thioflavin S Staining and Amyloid Fibril Quantification. To
determine Ab fibril plaque load, floating coronal sections fromAD and
wild-type mice, n5 4 for each group, were washed in miliQ water and
mounted on Fisherbrand Superfrost Plus microscope slides, before
being processed for 1% (w/v) Thioflavin S staining. All images were
taken with Leica (Mannheim, Germany) fluorescence microscope at
5 and with the same exposure across all images. The percent plaque
within specified areas of a series of hippocampal and frontal cortex
sections was quantified using ImageJ software from National Insti-
tutes of Health. Images were converted to 8-bit grayscale, and area of
interest was traced and determined. Brightness and B/W threshold
were adjusted appropriately and consistently across all images. The
area of plaque particles within the area of interest was obtained, and
the percent plaque was calculated. The series of sections of each
animal was averaged and grouped accordingly prior to statistical
analysis. The number of series of section per animal ranged from three
to 14 sections.
Three-Dimensional Human Neural Cell Culture Model of AD
Cells and Drug Treatments. HReN-mGAP AD ReN cell expres-
sion APPSwedish/London and Presenilin 1DE9 were previously described
(Choi et al., 2014). The HReN-mGAP AD ReN cells were three-
dimensional (3D)–differentiated for 7 weeks, as previously described
(Choi et al., 2014). The cultures were then harvested and analyzed
for the soluble (conditioned media) and insoluble Ab40/42/38 and
p-tau/tau levels, using Meso Scale Discovery electrochemilumines-
cence system. BPN-15606 (70 nM) and the same volume of DMSO
controls were treated in the last 4 weeks. The potential toxicity of
the drugs was monitored by CytoTox-ONE (lactate dehydrogenase)
assay after 1 week of the treatments. At the end of the treatments,
the soluble (media) and the insoluble fractions (5 M GuHCl-soluble
extracts) were collected and analyzed for Ab38, Ab40, and Ab42 with
MSD enzyme-linked immunosorbent assay (ELISA; V-Plex 6E10
Ab40/Ab42/Ab38 kit). The custom-made plates were used for detect-
ing total tau (BT2; ThermoFisher Scientific, Sommerset, NJ) and
pThr181 tau (At270; ThermoFisher Scientific, Sommerset, NJ). The
insoluble fraction was dissolved in 5MGuHCl, and pThr181 tau, total
tau, Ab40, Ab42, and Ab38 concentrations were determined by MSD
ELISA. The levels of the control protein Tuj1 were determined by
dot-blot analysis in the GuHCl lysates (data not shown).
Repeat-Dose Toxicity and Micronucleus Evaluation of
BPN-15606 in Rats
The objectives of this toxicity study were to determine maxi-
mum tolerated dose (MTD), characterize the potential toxicity, and
calculate toxicokinetic parameters of BPN-15606 in adult male
Sprague–Dawley rats (8–10 weeks of age) following daily po dose
administration for 7 consecutive days, and to evaluate its potential to
damage chromosomes or cause mitotic spindle abnormalities in vivo,
as measured by the incidence of micronucleus formation in RNA-
containing erythrocytes (bone marrow micronucleus assay). An over-
view of the study design is presented in Supplemental Table 8. Male
rats were administered BPN-15606 po for 7 consecutive days at 30,
100, or 300 mg/kg (groups 2, 3, and 4). A control group (group 1) was
given vehicle, 15% Labrasol/85% sterile water, at an equivalent dose
volume (10 ml/kg). A 375 mg/kg dose (group 5) was included for
determination of day 1 plasma drug levels. Clinical observations were
recorded twice daily.
All rats in groups 1, 2, and 3 (0, 30, and 100 mg/kg, respectively)
survived until their scheduled day 8 sacrifice, and all tissues specified
forhistologic evaluationwerecollected.Noneof thegroup4 (300mg/kg)
animals survived the 7-day dosing period: three were sacrificed in
moribund condition, and twowere found dead.Necropsy examinations
were performed on all rats, but, for group 4 animals, tissues for
histopathologic examination were collected only from those rats that
were sacrificed in moribund condition. Histopathology assessment
was conducted on all tissues collected from all animals in groups 1 and
3, and all tissues collected fromgroup 4 animals euthanizedmoribund.
From group 2 rats, the following tissues were examined histopatho-
logically: duodenum; jejunum; ileum; liver; lung; pancreas; spleen;
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stomach; and thymus, which were evaluated based on findings at the
higher dose levels.When present, grossly altered tissueswere examined
histopathologically from all group 1, 2, and 3 rats, and from moribund
sacrifice group 4 rats. Microscopic data were recorded, and a four-step
grading system (minimal, mild, moderate, and marked) was used to
define gradable changes. Terminology for data capture was consistent
with International Harmonization of Nomenclature and Diagnostic
Criteria as promulgated by the Society of Toxicologic Pathology.
The micronucleus component of this study was performed to
evaluate the ability of BPN-15606 to induce chromosomal damage in
bone marrow of male Sprague–Dawley rats. Rats (n 5 5/group) were
scheduled to receive single daily doses of BPN-15606 for 7 days at
30, 100, and 300 mg/kg/d (groups 2, 3, and 4, respectively), with
euthanasia scheduled 24 hours after the final dose. Animals receiving
300mg/kg/d were sacrificed in moribund condition on day 3 or 4 due to
excessive toxicity, and micronucleus formation was not evaluated; all
other treated animals survived to necropsy. Bone marrow samples
collected from the low and mid dose groups (30 and 100 mg/kg) were
evaluated for cytotoxicity and for micronucleus formation (see Sup-
plemental Table 8). Three bone marrow smear slides were prepared
per animal and fixed in absolute methanol. Positive control (cyclo-
phosphamide) slides generated in a separate good laboratory practice
(GLP)-compliant study were stained and included for scoring. Two
slides per animal were stained with acridine orange, coded, and
evaluated (blind) using epifluorescence microscopy. Under these condi-
tions, the cytoplasm of polychromatic erythrocytes (PCE) exhibits
orange fluorescence, and the DNA of any micronuclei present exhibits
yellow fluorescence. The criteria employed for identifying and quanti-
tating micronuclei are those described by Schmid (1975). Two principal
parameters were determined, as follows: 1) the number of PCE among
200 total red blood cells (RBC) per animal (PCE/RBC ratio), which
provides an index of bone marrow cytotoxicity, and 2) the number of
micronucleated RNA-positive PCE among a total of 2000 PCE per
animal, which provides an index of chromosomal damage.
Dose Escalation/7-Day Oral Gavage Toxicity and
Toxicokinetics Study of BPN-15606 in NHP
The objectives of this study were to determine the MTD of BPN-
15606, characterize potential toxicity, and calculate toxicokinetic
parameters of BPN-15606 in adult male and female cynomolgus
macaques following daily po dose administration at a near-MTD dose
of BPN-15606 for 7 consecutive days. In the dose escalation phase to
establish the MTD (phase A), male and female cynomolgus macaques
(n5 2/sex) were administered single doses of BPN-15606 at 3, 10, 30,
100, and 300mg/kg,with 2 to 4 days between each dose escalation (Fig.
10). Clinical signs were limited to emesis in the 100 and 300 mg/kg
groups. There were no apparent changes in the clinical pathology
parameters after single-dose administration. The plasma drug con-
centrations at the approximate Tmax increased in a dose-dependent
manner. Based on these results, 300mg/kgwas selected for evaluation
in the 7-day repeat-dose phase of the study (phase B). Comprehen-
sive evaluation of clinical pathology parameters (clinical chemistry,
hematology), gross pathology, and histopathologic parameters was
carried out at SRI International, according to their standardized
protocols. Tissues examined histopathologically included the follow-
ing: liver, lung, stomach, duodenum, colon, spleen, pancreas, thymus,
heart, brain, and kidney.
Results
In Vitro Effects of BPN-15606 on g-Secretase Activity.
During the past 4 years, we have synthesized and characterized
over 600 novel GSMs encompassing four closely related
scaffolds. Rigorous in vitro PK, pharmacodynamics (PD), and
toxicological evaluation of these compounds led to the discov-
ery of BPN-15606 (Fig. 1), which exhibits excellent drug-like
properties. Based on the balance of data summarized in
Supplemental Table 1, BPN-15606 progressed into nonclinical
development. BPN-15606 is a GSM and, as such, binds to an
allosteric site within the g-secretase enzymatic complex and
reduces the amount of secreted Ab42 (Crump et al., 2013).
In vitro, BPN-15606 exhibits an IC50 value of 7 nM for
attenuating the production of Ab42 by human SHSY5Y
neuroblastoma cells stably overexpressing human APP751
wild-type as measured by ELISA (Fig. 2). Importantly,
treatment with BPN-15606 does not affect Notch cleavage
at doses as high as 25 mM, as shown in Fig. 3. Proteolysis of
Notch by g-secretase is necessary for proper cellular differ-
entiation, and inhibition of Notch cleavage by g-secretase
inhibitors was previously associated with significant side
effects (Doody et al., 2013). Supplemental Tables 1 and 2
summarize the in vitro absorption, distribution, metabolism,
excretion, and toxicity (ADMET) properties of BPN-15606
(Supplemental Table 1) as well as the in vitro metabolites
identified in hepatocyte cultures from five species (Supple-
mental Table 2). Collectively, these studies established that
BPN-15605 has an acceptable in vitro ADMET profile to
enable in vivo studies and that there were no uniquely
human metabolites identified.
This GSM mechanism is illustrated in the anti-Ab
immunoprecipitation/matrix-assisted laser desorption/ionization
time of flight experiment depicted in Fig. 4, which shows that
neuronal cells treated overnight with 100 nM BPN-15606
completely eliminate the peak corresponding to Ab42 and
significantly reduce the Ab40 peak, whereas the size of the
Ab38 and Ab37 peaks is significantly increased. This GSM
mechanism appears to be free of the known toxicities associated
with inhibiting the g-secretase enzymatic complex that is
responsible for cleaving a large number of type 1 membrane
proteins (Wakabayashi andDe Strooper, 2008; Haapasalo and
Kovacs, 2011).
PK of BPN-15606 in Mice, Rats, and NHP. Plasma
concentrations of BPN-15606 measured in CD-1 mice and
Sprague–Dawley rats were used to determine PK parameters,
which are summarized in Supplemental Tables 3 and 4. Both
species showed bioavailability of greater than 60%. In male
non-naive cynomolgus monkeys (NHPs), plasma concentra-
tions of BPN-15606 were readily quantitated, facilitating
assessment of plasma PK parameters, which are summarized
in Supplemental Table 5. These data indicate bioavailability
is significantly less favorable relative to rodents (bioavailabil-
ity of 30.8% compared with mice and rats, which were both
greater than 60%).
Biochemical Efficacy of BPN-15606 in Mice and
Rats. BPN-15606 was repeatedly administered once daily
po to both mice (7 days) and rats (9 days) at various doses (see
Fig. 1. Chemical structure of BPN-15606.
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Fig. 5). BPN-15606 showed excellent dose-dependent efficacy in
both plasma and brain (mice) and plasma and CSF (rats) on
lowering of Ab42 and Ab40 levels. Importantly, BPN-15606
also showed dose-dependent exposures in these two studies (see
Supplemental Tables 6 and 7 for plasmadrug levels in the same
animals, in which the Ab peptide levels were measured). The
data in Fig. 5 also demonstrate excellent PD concordance
between plasma and brain (mouse) and plasma and CSF (rat)
for the ability of BPN-15606 to lower Ab42 and Ab40 levels
in a dose-dependent manner. The effects of BPN-15606 were
consistently greater in lowering plasma Ab levels than either
brain or CSF Ab levels probably due to the higher exposures of
free drug in plasma (see Supplemental Tables 6 and 7) as well
as the shorter half-life of plasma Ab peptides compared with
the central nervous system turnover of Ab peptides (Cirrito
et al., 2003). Time course studies were also carried out in
C57BL/6 mice following a single oral dose of BPN-15606
(25 mg/kg) (Fig. 6). As expected at this dose (25 mg/kg),
BPN-15606 showed a robust effect on both brain and plasma
Ab 42 and Ab40 levels, which began approximately 30–60
minutes following the single dose administration and lasted
for $24 hours.
Efficacy of BPN-15606 in PSAPP Transgenic Mice
Following Chronic Treatment. To determine whether
chronic BPN-15606 therapy could ameliorate Ab plaque
accumulation, the percentage of area occupied by Ab plaques
in PSAPP mice was quantified after 6 months of treatment
with BPN-15606 at an estimated daily dose of 10 mg/kg. It is
well established that the specific transgenicmousemodel used
in this study (PSAPP) develops Ab deposits by 2–3 months of
age with reliable onset of Ab neuritic plaques at 6 months
of age (Jankowsky et al., 2004; Zhang et al., 2016). Using
Thioflavin S–stained coronal sections and densitometry,
we confirmed that vehicle-treated female PSAPP mice at
9 months of age demonstrated significant accumulation of
Ab plaques (Fig. 7B) when compared with age-matched
BPN-15606–treated PSAPP mice (Fig. 7C) and nontransgenic
wild-type littermates (Fig. 7A). Regarding the quantitative
analysis of treatment impact, densitometric measurements
using NIH ImageJ software showed that chronic treatment
with BPN-15606 significantly reduced accumulation of Ab
neuritic plaques in both the hippocampus and cortex (Fig. 7,
D and E). Necropsies were carried out at the end of the study
with no significant adverse findings in either the vehicle or
BPN-15606 treatment groups (data not shown).
Efficacy of BPN-15606 on Soluble and Insoluble
Ab42, Ab40, Ab38, Total Tau, and p-Thr181 Tau in 3D
Human Neural Cell Cultures. BPN-15606 treatment
(70 nM) dramatically decreased soluble levels of Ab40, Ab42,
and Ab42/40 ratio while increasing Ab38 levels in the 3D
human neural cell culture model of AD (Fig. 8A). BPN-15606
treatment also decreased insoluble (5 M GuHCl-soluble
extracts) Ab40 and Ab42 levels (Fig. 8B). More importantly,
BPN-15606 treatment decreased insoluble pThr181 tau and
total tau levels (Fig. 8C), suggesting that BPN-15606 treat-
ment reduces p-tau pathology as well as Ab accumulation.
This result is not unexpected because other Ab42-lowering
compounds (e.g., BACE inhibitors) have also been shown to
impact p-tau pathology in this 3D human culture system (Choi
et al., 2014). Interestingly, Ab38 was not detected in insoluble
fractions, suggesting that the Ab38 species does not aggregate
with Ab40 or Ab42 at least not in 3D human neural cell
culture conditions.
Repeat-Dose Toxicity and Micronucleus Evaluation
of BPN-15606 in Rats. Animals in the vehicle- and 30mg/kg
BPN-15606–treated groups appeared normal throughout the
treatment period. Several clinical observations were noted in
the 100 and 300mg/kg dose groups during the study, including
hunched posture, hypoactivity, and discharge from nostrils,
eyes, and/or mouth. All animals in the 300 mg/kg dose group
were either found dead or sacrificed in moribund condition on
day 3 or 4, indicating this dose exceeded theMTD. One animal
Fig. 2. Concentration–response curves of
BPN-15606 using SHSY5Y-APP cell-based
MSD Ab triplex screening assay.
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in the 100 mg/kg toxicokinetic evaluation group died on day 4.
This animal died within approximately 1 minute of adminis-
tration of test article, and blood was present in the thoracic
cavity on gross necropsy evaluation. Thus, the death wasmost
likely due to procedural (gavage) error and not related to the
BPN-15606. The primary hematology findings consisted of
statistically significant, but small increases in RBC (↑10.5%),
hemoglobin (↑10.9%), and mean corpuscular hemoglobin
concentration (↑10.7%), and decrease in mean corpuscular
hemoglobin (↓6.9%) that were present in rats administered
100 mg/kg (group 3). The absolute number and percent of
reticulocytes were markedly decreased in the 100 mg/kg dose
group, falling to about 20% of the control values after 7 days of
treatment. Clinical chemistry changes were limited to small
reductions in serum protein and albumin concentrations at
100mg/kg (group 3), elevated serum cholesterol in both groups
2 (30 mg/kg) and 3, and lower triglycerides in group 3 com-
pared with the controls; these changes were not toxicologically
significant. Histopathologic lesions attributed directly (duo-
denum, stomach, liver) or indirectly (lung, pancreas, thymus)
to BPN-15606 were limited to the mid (100 mg/kg)- and high
(300 mg/kg)-dose groups, and were absent at the low dose
(30 mg/kg). The duodenum displayed mucosal inflammation,
edema,necrosis, erosion, ulceration, and/or serosal inflammation.
Fig. 3. Incubation of BPN-15606 (lanes 1–6) with H4-APP751 neuroglioma cells transfected with the Myc-tagged Notch (NDE) construct does not inhibit
Notch proteolysis. Alternatively, incubation with d-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (lanes 7–10)
potently inhibits Notch proteolysis.
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Histopathologic changes in the stomach included the following:
nonglandular epithelial hyperplasia, hyperkeratosis, erosion,
and ulceration; nonglandular submucosal fibrosis, edema,
increased inflammation, and fibrosis; and/or serosal inflamma-
tion. Hepatocyte basophilia, hypertrophy, and lipidosis were
present in liver at the high (lethal) dose. Other microscopic
observations in lung, pancreas, and thymus were secondary
to malaise associated with gastrointestinal lesions.
BPN-15606 did not induce micronuclei in the bone marrow
of rats following 7 days of treatment at 30 or 100 mg/kg,
indicating it does not appear to have clastogenic potential
in vivo.
BPN-15606 absorption was prolonged, with Tmax for indi-
vidual animals occurring at 4–24 hours, depending on dose.
The apparently continuous absorption of BPN-15606 from the
gastrointestinal tract is most likely the result of slow dissolu-
tion rate caused by poor aqueous solubility. The mean Tmax
was 13.3 hours (day 1) or 6.7 hours (day 7) in the 30mg/kg dose
group. The time to the peak plasma drug level was later on day
1 in the 100 and 300 dose groups, with a mean value of 18.7
hours. Mean values for Cmax and AUClast on day 1 increased
with dose, although the increases were not proportional to
dose from 100 to 300 mg/kg. The less than dose-proportional
increase in systemic exposure (Cmax and area under the
curve) of BPN-15606 is also most likely due to poor solubility.
Day 7 predose samples all contained a significant concentra-
tion of BPN-15606, which resulted in exposure parameters
thatweremarkedly higher on day 7 than day 1 (see Fig. 9). The
mean residence time to the last time point values ranged from
9.1 hours for the 30 mg/kg group on day 1 to 13.6 hours for the
100 mg/kg group on day 1. Thus, significant drug accumula-
tion of BPN-15606 was observed in rats following once-daily
dosing for 7 days.
In summary, BPN-15606–related mortalities occurred in
the 300 mg/kg group. Adverse effects on the erythroid system
are consistent with responses to acute hemorrhaging, which is
supported by histopathologic findings of necrosis, erosion, and
ulceration in stomach and duodenum. The liver was also
identified as a target organ, based on microscopic evidence of
basophilia, hypertrophy, and lipidosis in liver of rats treated
Fig. 4. Matrix-assisted laser desorption/
ionization time of flight mass spectrum
data of anti–Ab17–24 monoclonal anti-
body (4G8) immunoprecipitates.
Fig. 5. Levels of Ab42 (top) and Ab40 (bottom) in plasma, brain, or CSF following daily oral administration of either vehicle or BPN-15606. (A) Ab
peptides of male C57BL/6J mice (n = 10/dose) were measured in plasma and brain following a 7-day oral treatment course. (B) Ab peptides of male
Sprague–Dawley rats (n = 14/dose) were measured in plasma and CSF following a 9-day treatment course. Ab peptide levels were determined using
Meso Scale Sector 6000 Multiplex assays. Student t test; *P, 0.05; **P, 0.01; ***P, 0.001.
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with 300 mg/kg. There was no significant suppression of
polychromatic erythrocytes (PCE) among RBC in bone mar-
row, and no statistically significant increase in the frequency
of micronucleated PCE was seen at any dose level evaluated
compared with vehicle controls. No toxicologically signifi-
cant effects were observed in the 30 mg/kg dose group. The
no-observed-effect level (NOEL) of BPN-15606 is thus 30
mg/kg/d when given po daily for 7 consecutive days to rats,
and the MTD of BPN-15606 is considered to be approximately
100 mg/kg/d.
Dose Escalation/7-Day Oral Gavage Toxicity and
Toxicokinetics Study of BPN-15606 in NHP. In the dose
escalation phase,male and female cynomolgusmacaqueswere
administered single doses of BPN-15606 by the oral route at
doses of 3, 10, 30, 100, and 300 mg/kg, with 2–4 days between
each dose escalation (Fig. 10). Clinical signs were limited to
emesis in the 100 and 300 mg/kg groups. There were no
apparent changes in the clinical pathology parameters after
single-dose administration for any of the doses evaluated. The
plasma drug concentrations at the approximate Tmax in-
creased in a dose-dependent manner. Based on these results,
300 mg/kg was selected for the 7-day repeat dose phase of the
study (phase B). Daily oral administration of 300 mg/kg BPN-
15606 resulted in clinical signs of emesis, reduced appetite,
and reduced stool. Weight loss occurred with repeat-dose
administration, which ranged from 3.2% to 10.5%. Based on
the adverse clinical signs and weight loss, the study was
terminated 1 day early (after 6 days of dosing).
Toxicokinetic analysis of plasma drug levels identified a
Tmax of 2–4 hours, and mean plasma half-life was 8.7 hours
and 10.2 hours, on days 1 and 6, respectively. Daily adminis-
tration of BPN-15606 led to accumulation, and, based on the
AUClast, exposure to BPN-15606 was about 1.7-fold higher on
day 6 than on day 1 (Fig. 11).
Histopathological findings that are considered to be related
to repeated dose administration of BPN-15606 (300 mg/kg)
were present in kidney and possibly liver. Renal findings
included mild to moderate proximal tubular necrosis, casts,
and dilation with cortical and medullary subacute inflamma-
tion in two male monkeys and one of two female monkeys.
Hepatic findings were less convincing, but included minimal
sinusoidal leukocytosis in two male monkeys and moderate
focal fatty infiltration in one female monkey. These histopath-
ological changes are consistent with the increased creatinine
Fig. 6. Levels of Ab42 (A and B) and Ab40 (C and D) in plasma and brain or following single oral administration of either vehicle or BPN-15606. C57BL/
6mice (n = 5/time point) were dosed with 25mg/kg BPN-15606 or vehicle po. Animals were then sacrificed at the indicated time point (0.5–24 hours), and
the levels of Ab42 and Ab40 peptides were quantified using Meso Scale Sector 6000 Multiplex assays. Student t test; *P, 0.05; **P, 0.01; ***P, 0.001.
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(renal effects) and increased total bilirubin (hepatic effects)
that were noted in clinical chemistry analysis (data not
shown). Adverse effects on the kidneys may be responsible
for the decreased platelets and reticulocytes due to lower
erythropoietin levels from kidneys and subsequent reduction
in hematopoiesis. Changes in serum triglycerides and choles-
terol are likely to be related to the observed weight loss, but
may also be a direct effect of BPN-15606.
In summary, administration of a single dose of BPN-15606
to cynomolgus monkeys at doses of 3, 10, 30, 100, and 300
mg/kg resulted in emesis only at the 100 and 300 mg/kg dose
levels. There were no other adverse findings noted during the
single-dose administration phase. Based on these data, the
MTD after a single-dose administration was estimated to
be $300 mg/kg, and the NOEL after a single dose was 30
mg/kg. Administration of 300 mg/kg BPN-15606 po daily for
6 consecutive days to cynomolgus monkeys was associated
with weight loss and adverse cortical and medullary renal
findings, which were supported by changes in clinical chem-
istry parameters. Based on these observations and under the
conditions of this study, the MTD is estimated to be signifi-
cantly below 300 mg/kg/d. A no-observed-adverse-effect level
(NOAEL) could not be determined for the repeat-dose range-
finding phase (phase B).
Discussion
We have shown in vivo PK/PD properties with BPN-15606,
have characterized key toxicological properties of the mole-
cule, and have demonstrated significant dose-dependent
biochemical efficacy (lowering of CSF and brain Ab42 levels
by ∼40% at doses as low as 5–10 mg/kg in rats and mice,
respectively; Fig. 5) and dose-proportional exposures from 5
to 50 mg/kg in both species (Supplemental Tables 6 and 7).
At higher doses (25 mg/kg), BPN-15606 can almost totally
eliminate (∼70–75% lowering) Ab42 levels in both brain and
CSF of mice and rats, respectively, whereas plasma Ab42 is
lowered by .90% in both species. These in vivo results are
relevant because the CSF Ab42 biomarker has been and is
currently being used in clinical trials to assess target engage-
ment (Fleisher et al., 2008; Coric et al., 2012; Lucey et al.,
2015; Soares et al., 2016; Toyn et al., 2016).
BPN-15606 fulfills practically all of our lead identification
profile criteria for a clinical candidate. Since the discovery of
this pyridazine scaffold, further optimization efforts have
been undertaken through synthesis of an additional 134
pyridazine GSMs, all of which are close structural analogs of
BPN-15606 (Wagner et al., 2016) with the goal of identifying
one or more backup compounds to BPN-15606 that are free
of any significant liabilities. Furthermore, as we pursue a
therapy for a challenging disorder such as AD, establishing
a series of credible backup lead molecules to BPN-15606 is
critically important.
We have previously shown that attenuation of Ab42 levels
over an extended period of time (7 months) dramatically
reduces the number of amyloid plaques in Tg2576 trans-
genic mice (Kounnas et al., 2010). These data were gen-
erated following chronic oral treatment with 50 mg/kg/d
aminothiazole-bridged aromatic GSM, or aminothiazole-
bridged aromatic GSM (AGSM), similar in structure and
Fig. 7. Representative coronal sections of Thioflavin S–stained images. Three-month-old PSAPP mice were treated with BPN-15606 (10 mg/kg/d) or
vehicle via laced chow for 6 months. Grayscale images represent PSAPPmice at 9 months of age. (A) Representative coronal section of age-matched wild-
type negative control littermates. (B) Representative coronal section of vehicle-treated PSAPP mice. (C) Representative coronal section of BPN-
15606–treated PSAPP mice. Ab accumulation in Thioflavin S–stained coronal sections was quantified using densitometry in 9-month-old PSAPP mice
chronically treated for 6 months. BPN-15606–treated cohort had significantly reduced accumulation of Ab plaques in both the hippocampus (D) and
cortex (E). n = 10 per group. *P , 0.05; **P , 0.005; ***P , 0.0005.
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function to the GSMs that we have been optimizing and
characterizing over the past 4 years. TheAGSMs act through a
mechanism similar to our new lead GSM, by potently inhibit-
ing Ab42 and Ab40 while potentiating Ab38 and Ab37.
Biochemical and Pathologic Efficacy in Rodents and
a 3D Human Neural Cell Model. In this study, we have
shown that a potent novel pyridazine C-ring–containing GSM
(BPN-15606) significantly lowered Ab42 levels in plasma and
brain/CSF of mice and rats at doses 10-fold lower than doses
previously required for AGSMs (Fig. 5) (Kounnas et al., 2010).
In addition, BPN-15606 demonstrated dose-dependent effi-
cacy in both mice and rats, as well as dose-dependent
exposures at doses ranging from 10 to 50 mg/kg in mice and at
doses ranging from 5 to 50 mg/kg in rats (Supplemental
Tables 6 and 7). Importantly, the concentrations of free drug
achieved in the brain at doses as low as 5–10 mg/kg in rats and
mice, respectively, are still almost twofold above the in vitro
IC50 for lowering Ab42. The PK parameters of BPN-15606
in mouse and rat (Supplemental Tables 3 and 4) support the
significant dose-dependent efficacies and dose-dependent ex-
posures achieved in the two independent efficacy studies.
In the chronic (6-month) efficacy study in the PSAPP
transgenic mice, treatment with BPN-15606 at a dose of
10 mg/kg/d starting with 3-month-old PSAPP mice, which
presumably already had significant amyloid deposition, at
9 months of age, there resulted a substantial reduction in the
Fig. 8. The impact of BPN-15606 on soluble and insoluble Ab40/Ab42/Ab38 and p-tau/total-tau levels in 3D human neural cell culture model of AD. The
AD ReN cells (HReN-mGAP30) were 3D-differentiated for a total of 7 weeks, whereas the 70 nMBPN-15606 and DMSO vehicle controls were treated for
the last 4 weeks. (A) Relative levels of Ab40, Ab42, and Ab38 in soluble (media) fractions. BPN-15606 treatment dramatically decreased Ab42, Ab40
levels, as well as Ab42/40 ratio and increased Ab38 levels. (B) Relative levels of Ab40 and Ab42 in insoluble (5 M GuHCl-soluble) fractions in the 3D-
cultured cells with or without BPN-15606 treatment. (C) Relative levels of insoluble total and pThr181 tau. (D) The 1-week-old treated media were
analyzed by the Cytotox cell death lactate dehydrogenase assay. BPN-15606 treatments did not induce any significant toxicity (n$ 4 per each sample).
Student t test; *P , 0.05; **P , 0.01; ***P , 0.001.
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amount of Thiofavin S–positive neuritic plaques in the
BPN-15606–treated PSAPP mice compared with the vehicle-
treated 9-month-old PSAPP mice (Fig. 7). These data demon-
strating mitigation of neuropathology were consistent with
the ability of BPN-15606 to substantially reduce the levels of
insoluble Ab42 as well as insoluble total tau and pThr181 tau
in the 3D human neural cell culture model of AD, suggesting
that BPN-15606 reduced p-tau pathology and Ab42 accumu-
lation (Fig. 8).
Repeat-Dose Toxicity. In addition to potency, BPN-
15606 has acceptable PK/PD properties, including bioavail-
ability, half-life, and clearance (Supplemental Tables 3, 4,
and 5). This PK/PD profile is reflected in the ability of the
compound to sustain significant lowering of Ab42 for $24
hours in mouse brain after a single dose (Fig. 6). BPN-15606
has undergone extensive preclinical study, including in vitro
ADMET and metabolite profiling in five species (Supplemen-
tal Tables 1 and 2), which confirms the absence of any unique
Fig. 9. Plasma concentrations of BPN-15606 in male
Sprague–Dawley rats on days 1 and 7. The test article
(BPN-15606) was administered po daily for 7 days. All
animals in the 300 mg/kg group were either found dead
or euthanized on day 3 or 4.
Fig. 10. Design of NHP dose range-finding study. A dose escalation phase was used to determine the MTD that was followed by a 7-day repeat-dose
phase at the MTD. Toxicokinetic time points: predose, 1, 2, 4 (Tmax), 8, and 24 hours.
aEstimated based on clinical signs and clinical pathology in dose
escalation. bInterval between doses was flexible and based on response/tollerance.
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human metabolites. Additionally, this compound demon-
strated aNOEL in the rat dose range-finding and toxicokinetic
study of $30 mg/kg after 7 days of dosing (Supplemental
Table 9) and a NOAEL of 50 mg/kg in the rat efficacy study
after 9 days dosing in which significant efficacy was achieved
at the lowest dose tested of 5 mg/kg (Fig. 5), suggesting a$10-
fold safety margin based on dose. In this same rat study, the
MTD was estimated at 100 mg/kg. BPN-15606 demonstrated
a NOAEL of 30 mg/kg after a single dose in cynomolgus
macaques, based on emesis noted at higher doses (Fig. 10;
Supplemental Table 9). In the NHP dose range-finding and
toxicokinetic study, a single-dose escalation phase was used to
determine the MTD (300 mg/kg), which was followed by a
repeat-dose phase of 6 days at the MTD. Emesis limited
treatment duration to 6 days, which was accompanied by a
weight loss of up to 10.5% relative to day 1, which was most
likely related to emesis and reduced food consumption. There
were no gross findings at necropsy, and histopathologic
findings were limited to mild to moderate proximal tubular
necrosis with subacute inflammation in two of two males and
one of two females. In the liver, the histopathologic findings
were reported as “less convincing” but included minimal
sinusoidal leukocytosis in two of two males and moderate
focal fatty infiltration in one of two females. As repeated oral
administration of 300 mg/kg BPN-15606 to cynomolgus mon-
keys was associated with dose-limiting adverse effects after
6 days, doses of 100, 60, 30, and 10 mg/kg are planned for the
Investigational New Drug-enabling 28-day GLP study.
Further Preclinical and Clinical Development. To
date no GSM has been tested in Alzheimer’s patients. In a
series of excellent studies recently published by Bristol-Myers
Squibb (Soares et al., 2016; Toyn et al., 2016), the GSM, BMS-
932481, demonstrated robust translation across several pre-
clinical species as well as human subjects. Unfortunately, in
repeated oral dosing studies in humans, BMS-932481 elicited
transient elevations in plasma concentrations of enzymes
associated with hepatic toxicity, which precluded robust
lowering Ab peptides through oral dosing, thus terminating
further clinical development of this once promising GSM. The
authors suggested that cause of the elevation in hepatic
enzymes by BMS-932481 was unlikely mechanism-based
and possibly the result of the high degree of nonspecific
protein binding that demanded plasma exposures in the
micromolar range to achieve significantmodulation of g-secretase
in brain (Toyn et al., 2016). Recently, another GSM (FRM-36143)
was published by groups from McGill University (Montreal,
Quebec, Canada) and FORUM Pharmaceuticals, which showed
reasonable in vitro (EC50 5 35 nM) and in vivo potencies
(maximum 58% reduction of Ab42 in rat CSF at a dose of
30mg/kg); however, the lack of any reported repeated exposure
toxicity and safety data makes a prediction on the suitability of
this compound for future clinical studies uncertain at this point
(Blain et al., 2016).
Decisions on the future of BPN-15606 await the results of
the Food and Drug Administration–reviewed planned 28-day
GLP Investigational New Drug-enabling studies, although,
based on the summation of the results of the studies presented
on BPN-15606 in this work, in combination with traditional
allometric scaling algorithms, we project that slightly less
than micromolar plasma exposures will be necessary to elicit
significant lowering of Ab42 in human brain and should
require much lower doses than those reported for BMS-
932481 by Toyn et al. (2016) and Soares et al. (2016).
Hopefully, BPN-15606 will ultimately be granted the oppor-
tunity to be tested in the appropriate human subjects and
patients.
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